Details

Autor(en) / Beteiligte

• Fassnacht, Martin
• Terzolo, Massimo
• Allolio, Bruno
• Baudin, Eric
• Haak, Harm
• Berruti, Alfredo
• Welin, Staffan
• Schade-Brittinger, Carmen
• Lacroix, André
• Jarzab, Barbara
• Sorbye, Halfdan
• Torpy, David J
• Stepan, Vinzenz
• Schteingart, David E
• Arlt, Wiebke
• Kroiss, Matthias
• Leboulleux, Sophie
• Sperone, Paola
• Sundin, Anders
• Hermsen, Ilse
• Hahner, Stefanie
• Willenberg, Holger S
• Tabarin, Antoine
• Quinkler, Marcus
• de la Fouchardière, Christelle
• Schlumberger, Martin
• Mantero, Franco
• Weismann, Dirk
• Beuschlein, Felix
• Gelderblom, Hans
• Wilmink, Hanneke
• Sender, Monica
• Edgerly, Maureen
• Kenn, Werner
• Fojo, Tito
• Müller, Hans-Helge
• Skogseid, Britt

Titel

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

Ist Teil von

• The New England journal of medicine, 2012-06, Vol.366 (23), p.2189-2197

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2012

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In this large international study of patients with adrenal cancer, a rare, treatment-refractory disease, mitotane plus a combination of etoposide, cisplatin, and doxorubicin had greater antitumor activity than mitotane plus streptozotocin. Adrenocortical carcinoma is a rare cancer (estimated incidence, 0.7 to 2.0 cases per 1 million population per year) 1 , 2 with a poor prognosis; the 5-year survival rate is less than 15% among patients with metastatic disease. 3 – 7 Mitotane is the only drug approved for the treatment of adrenocortical carcinoma and is used both as adjuvant therapy and for advanced disease, 8 – 14 although its efficacy has never been shown in a randomized trial. The experience with other antineoplastic drugs for the treatment of this disease is even more limited. Current treatment strategies for advanced disease are based exclusively on retrospective series . . .